ClinicalTrials.gg
CompletedNCT01289821Updated Mar 15, 2017Results posted

First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib

A Phase 2 interventional study of Regorafenib (Stivarga, BAY73-4506) and Oxaliplatin in Colorectal Neoplasms, sponsored by Bayer. Completed at 18 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-15.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.

Enrollment
30th of 58
54 · median 55
Started
2011
with 2 others
Phase 2
29 of 59
5 open now
Registered
4th of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one is the 30th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2011, is one of 29 in phase 2, and was the 4th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing regorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a study to evaluate the efficacy (effectiveness) and the safety of regorafenib when given in combination with chemotherapy mFOLFOX6 as first line therapy in patients with metastatic colorectal cancer (CRC). mFOLFOX6 is an approved chemotherapy. Regorafenib is an oral (i.e. taken by mouth) multi-targeted kinase inhibitor. A kinase inhibitor targets certain key proteins that are essential for the survival of the cancer cell. By specifically targeting these proteins, regorafenib may stop cancer growth. The growth of the tumor may be decreased by preventing these specific proteins from functioning.

The primary endpoint (the most meaningful result to be tracked) of this study is based on the rate of response, i.e. the disease getting smaller. The aim is to show that the therapy of colorectal cancer with mFOLFOX6 in combination with regorafenib improves the response rate observed for the standard therapy only.

03

Conditions studied

  • Colorectal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged ≥ 18 years
  • Histological or cytological documentation of adenocarcinoma of the colon or rectum
  • Suitable to receive mFOLFOX6 regimen as treatment
  • At least 1 as per version 1.1
  • Unresectable or unlikely becoming resectable metastatic disease
  • (ECOG) Performance Status of 0 or 1
  • of at least 3 months
  • Adequate bone marrow, liver, and renal function

Exclusion criteria

Exclusion Criteria:

  • Prior systemic anticancer therapy for colorectal cancer (CRC). chemotherapy for CRC (Stage I, II, III) is permitted, if the adjuvant therapy ended > 6 months before screening and recurrent disease was documented.
  • Prior treatment with antivascular endothelial growth factor (anti-VEGF) agents and any signal transduction inhibitors (STIs)
  • Uncontrolled hypertension
  • Subjects with symptoms, signs, or history of
  • Any hemorrhage or bleeding event ≥ (CTCAE) Grade 3 within 4 weeks of start of study treatment
  • Sensory neuropathy (> CTCAE Grade 1), unresolved toxicity > CTCAE Grade 1 attributed to any prior therapy/procedure excluding alopecia
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Regorafenib + oxaliplatin/folinic acid/5-FU (mFOLFOX6)

    On Day 1, participants received 85 mg/m\^2 oxaliplatin as a 2-hour intravenous (IV) infusion and folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid) as a 2-hour IV infusion. Once the initial infusion was completed, participants received 5-FU 400 mg/m\^2 IV bolus injection immediately followed by a 5-FU 2400 mg/m\^2 IV infusion for 46 hours. The next cycle of mFOLFOX6 was administered on Day 15 to 17. Participants received Regorafenib (Stivarga, BAY73-4506) 160 mg orally (po) once daily (qd) on Days 4 to 10 and Days 18 to 24. One cycle comprised 28 days.

    Drug: Regorafenib (Stivarga, BAY73-4506) · Drug: Oxaliplatin · Drug: Folinic acid · Drug: 5-FU (mFOLFOX6)

Interventions

  • Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.

  • On day 1 and day 15 of each cycle, participants will receive 85 mg/m\^2 oxaliplatin as a 2 hour i.v. infusion.

  • On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid) as a 2 hour i.v. infusion.

  • Participants will receive a 400 mg/m\^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m\^2 5 FU 46 hour i.v. infusion.

06

What researchers measure

Primary outcomes

  1. Objective Response (OR)

    OR was defined as the best tumor response (confirmed complete response \[CR\] or partial response \[PR\]) observed by MRI or CT scan assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. CR and PR were confirmed not earlier than 4 weeks following the initial detection of response. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). Any pathological lymph nodes (whether target or non target) must have a reduction in short axis to \< 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing nontarget lesions and no appearance of new lesions.

    Time frame: From start of treatment until 30 days after termination of study medication, an average of 47 weeks. Assessed every 8 weeks.

Secondary outcomes

  1. Overall Survival (OS)

    OS was calculated as the time from first date of receiving study treatment to date of death due to any cause. Participants alive at the time of analysis were censored at their last date of follow-up.

    Time frame: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

  2. Progression-free Survival (PFS)

    PFS was defined as time from the date of start of study treatment to the date of first observed disease progression (radiological according to central assessment or clinical), or death due to any cause, if death occurred before progression was documented. PFS for participants without disease progression or death at the date of database cutoff were right-censored at the last date of tumor assessment. Participants who had no tumor evaluation after baseline and no clinical progression post baseline and who did not die were censored at Day 1 in the analysis. PD = At least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non target lesions or the appearance of one or more new lesions will also constitute PD.

    Time frame: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

  3. Disease Control (DC)

    DC was defined as the proportion of participants who had a best response rating of CR, PR, or stable disease (SD) according to RECIST criteria that was achieved during treatment or within 30 days after termination of study treatment. CR and PR were confirmed not earlier than 4 weeks following the initial detection of response. A minimum of 8 weeks (allowing a minus 7-day time window) between start of study treatment and the first follow-up tumor assessment with SD as response was required to assign SD as best overall response.

    Time frame: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

  4. Duration of Response (DOR)

    DOR was defined as the time from the date of first documented objective response of PR or CR, whichever was noted earlier, to first subsequent disease progression or death (if death occurred before progression was documented). DOR was defined for responders only (that is, subjects with CR or PR). DOR for subjects without disease progression or death before progression was right censored at the date of their last tumor assessment.

    Time frame: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

  5. Duration of Stable Disease (DOSD)

    DOSD was only evaluated in participants failing to achieve a best response of CR or PR, but who achieved SD. DOSR was defined as the time (in days) from date of start of study treatment to the date at which disease progression or death (if death occurred before progression was first documented). The date the tumor scan was performed was used for this calculation. DOSD for participants without disease progression or death before progression at the time of analysis were censored at the date of their last tumor assessment.

    Time frame: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

07

Results

Posted Sep 4, 2013

Participant flow

Male or female participants with histological or cytological documentation of adenocarcinoma of the colon or rectum that was unresectable or unlikely of becomining resectable, who were at least 18 years of age and were suitable to receive mFOLFOX6 regimen as first line treatment could participate in this study at 16 centers in 7 countries.

Treatment Period
Participant flow — Treatment Period
MilestoneRegorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Started54
Participants received regorafenib54
Completed0
Not completed54
Withdrew: Withdrawal by subject1
Withdrew: Physician decision3
Withdrew: Adverse event4
Withdrew: Radiological progression43
Withdrew: Clinical progression2
Withdrew: Therapeutic procedure required1
Safety Follow-up Period
Participant flow — Safety Follow-up Period
MilestoneRegorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Started54
Completed49
Not completed5
Withdrew: Withdrawal by subject1
Withdrew: Protocol violation3
Withdrew: Unspecified reason1
Survival Follow-up Period
Participant flow — Survival Follow-up Period
MilestoneRegorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Started52
Completed34
Not completed18
Withdrew: Protocol violation1
Withdrew: Lost to follow-up1
Withdrew: Clinical endpoint reached16

Outcome measures

PrimaryObjective Response (OR)

OR was defined as the best tumor response (confirmed complete response \[CR\] or partial response \[PR\]) observed by MRI or CT scan assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. CR and PR were confirmed not earlier than 4 weeks following the initial detection of response. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). Any pathological lymph nodes (whether target or non target) must have a reduction in short axis to \< 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing nontarget lesions and no appearance of new lesions.

Time frame:
From start of treatment until 30 days after termination of study medication, an average of 47 weeks. Assessed every 8 weeks.
Reported as:
Number · Proportion of participants
Objective Response (OR)
Proportion of participantsRegorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Objective Response (OR)0.4390
Statistical analysis
  • Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) · One-sample exact binomial test · p = 0.36 · Percentage of participants: 43.90 · 80% CI 33.19 to 55.09
SecondaryOverall Survival (OS)

OS was calculated as the time from first date of receiving study treatment to date of death due to any cause. Participants alive at the time of analysis were censored at their last date of follow-up.

Time frame:
From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks
Reported as:
Median · Days
Overall Survival (OS)
DaysRegorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Overall Survival (OS)772 (646 to 1089)
SecondaryProgression-free Survival (PFS)

PFS was defined as time from the date of start of study treatment to the date of first observed disease progression (radiological according to central assessment or clinical), or death due to any cause, if death occurred before progression was documented. PFS for participants without disease progression or death at the date of database cutoff were right-censored at the last date of tumor assessment. Participants who had no tumor evaluation after baseline and no clinical progression post baseline and who did not die were censored at Day 1 in the analysis. PD = At least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non target lesions or the appearance of one or more new lesions will also constitute PD.

Time frame:
From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks
Reported as:
Median · Days
Progression-free Survival (PFS)
DaysRegorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Progression-free Survival (PFS)258 (222 to 334)
SecondaryDisease Control (DC)

DC was defined as the proportion of participants who had a best response rating of CR, PR, or stable disease (SD) according to RECIST criteria that was achieved during treatment or within 30 days after termination of study treatment. CR and PR were confirmed not earlier than 4 weeks following the initial detection of response. A minimum of 8 weeks (allowing a minus 7-day time window) between start of study treatment and the first follow-up tumor assessment with SD as response was required to assign SD as best overall response.

Time frame:
From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks
Reported as:
Number · Proportion of participants
Disease Control (DC)
Proportion of participantsRegorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Disease Control (DC)0.8537
SecondaryDuration of Response (DOR)

DOR was defined as the time from the date of first documented objective response of PR or CR, whichever was noted earlier, to first subsequent disease progression or death (if death occurred before progression was documented). DOR was defined for responders only (that is, subjects with CR or PR). DOR for subjects without disease progression or death before progression was right censored at the date of their last tumor assessment.

Time frame:
From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks
Reported as:
Median · Days
Duration of Response (DOR)
DaysRegorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Duration of Response (DOR)257 (176 to 349)
SecondaryDuration of Stable Disease (DOSD)

DOSD was only evaluated in participants failing to achieve a best response of CR or PR, but who achieved SD. DOSR was defined as the time (in days) from date of start of study treatment to the date at which disease progression or death (if death occurred before progression was first documented). The date the tumor scan was performed was used for this calculation. DOSD for participants without disease progression or death before progression at the time of analysis were censored at the date of their last tumor assessment.

Time frame:
From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks
Reported as:
Median · Days
Duration of Stable Disease (DOSD)
DaysRegorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Duration of Stable Disease (DOSD)231 (167 to 259)

Adverse events

Collected over From start of study treatment until 4 weeks following the last dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)—25/53 (47.2%)53/53 (100%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventRegorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Surgical and medical procedures - Other, specifySurgical and medical procedures7/53
DiarrheaGastrointestinal disorders3/53
Small intestinal obstructionGastrointestinal disorders3/53
FeverGeneral disorders3/53
Thromboembolic eventVascular disorders3/53
Febrile neutropeniaBlood and lymphatic system disorders1/53
Lymph node painBlood and lymphatic system disorders1/53
Acute coronary syndromeCardiac disorders1/53
Atrial fibrillationCardiac disorders1/53
Atrial flutterCardiac disorders1/53
Most frequent other events
Showing 10 of 79
Most frequent other events
EventRegorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
DiarrheaGastrointestinal disorders37/53
Neutrophil count decreasedInvestigations35/53
FatigueGeneral disorders34/53
HypertensionVascular disorders30/53
Abdominal painGastrointestinal disorders28/53
NauseaGastrointestinal disorders28/53
ParesthesiaNervous system disorders28/53
Platelet count decreasedInvestigations25/53
Mucositis oralGastrointestinal disorders24/53
Peripheral sensory neuropathyNervous system disorders24/53

Baseline characteristics

Age, Customized
Age, Customized(Participants)Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
< 65 years33
65 - 75 years18
> 75 years3
Sex/Gender, Customized
Sex/Gender, Customized(Paricipants)Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Female26
Male28
Caucasian
Caucasian(Participants)Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
Number54
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) at study entry
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) at study entry(Participants)Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
035
119
Stage at initial diagnosis
Stage at initial diagnosis(Participants)Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)
I1
IIA5
IIIB3
IIIC4
IV41
08

Study locations

18 sites
  • Chicago, Illinois 60611-2906, United States
  • Concord, New South Wales 2139, Australia
  • Woodville South, South Australia 5011, Australia
  • Bruxelles - Brussel, 1070, Belgium
  • Edegem, 2650, Belgium
  • Leuven, 3000, Belgium
  • Stuttgart, Baden-Württemberg 70199, Germany
  • Oldenburg, Niedersachsen 26133, Germany
  • Herne, Nordrhein-Westfalen 44625, Germany
  • Dresden, Sachsen 01307, Germany
  • Napoli, Campania 80131, Italy
  • Genova, Liguria 16132, Italy
  • Ancona, Marche 60126, Italy
  • Santander, Cantabria 39008, Spain
  • Barcelona, 08035, Spain
  • Madrid, 28034, Spain
  • Glasgow, G12 0YN, United Kingdom
  • Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Kohne CH, Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D, Mross KB. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol. 2013 Jun;24(6):1560-7. doi: 10.1093/annonc/mdt056. Epub 2013 Mar 13. PubMed 23493136 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Mar 2012 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2011
First posted
Feb 4, 2011
Start
Feb 2011
Primary completionActual
Mar 2012
CompletionActual
Jun 2014
Results first posted
Sep 4, 2013
Last update
Mar 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01289821
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 4, 2011
Start date
Feb 2011
Primary completion
Mar 2012
Completion
Jun 2014
Results posted
Sep 4, 2013
Last update
Mar 15, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion